PharmaPoint: Irritable Bowel Syndrome - Global Drug Forecast and Market Analysis to 2023

Irritable Bowel Syndrome (IBS) is a common disorder characterized by abdominal discomfort associated with altered bowel function. Although IBS is not a life-threatening disorder, it has a considerable effect on patients' quality of life (QOL). In terms of volume, the IBS market is a large, albeit naive, one, with only a small number of pharmacotherapies indicated for the treatment of the disorder, and it is also characterized by significant unmet needs.

As of October 2014, there were four products indicated for IBS in the 7MM. These include the constipation-predominant IBS (IBS-C) therapies, Sucampo/Takeda/Abbott's Amitiza (lubiprostone) and Ironwood/Actavis/Almirall/Astellas' Linzess (linaclotide), and the diarrhea-predominant IBS (IBS-D) therapies, Prometheus' Lotronex (alosetron) and Astellas' Irribow (ramosetron). Antidepressants and antibiotics (mainly Salix/Alfa Wassermann/Norgine/Bama-Geve's Xifaxan [rifaximin]), are also commonly used off-label to treat IBS. GlobalData anticipates that four new therapies have the potential to enter the IBS market during the 2013-2023 forecast period. This includes Furiex's (Actavis') eluxadoline and Menarini's ibodutant for IBS-D, and Synergy's plecanatide and AstraZeneca/Ardelyx's tenapanor for IBS-C. In addition, Xifaxan is in development for IBS-D, and has the potential to gain a label expansion for this indication during the forecast period.

Full Report Details at
- http://www.fastmr.com/prod/966203_pharmapoint_irritable_bowel_syndrome_global_drug.aspx?afid=301

Highlights

Key Questions Answered

* What do physicians think about Ironwood/Actavis/Almirall/Astellas' Linzess and what will be the impact in the IBS market following its launch in 2012 in the US and 2013 in the 5EU region?
* What will be the uptake of Salix/Alfa Wassermann/Norgine/Bama-Geve's Xifaxan following its anticipated label-expansion for IBS-D and how will it impact the treatment paradigm for IBS?
* What is the significance of late-phase pipeline products for IBS and how will their launch shape the future treatment landscape in IBS?
* What are the significant unmet needs in the IBS market?
* What are the remaining opportunities in the IBS market?

Key Findings

* The IBS market value will be driven by the increasing uptake of Ironwood/Actavis/Almirall/Astellas' Linzess and its expected launch in all the major European markets and Japan, the anticipated label expansion of Salix/Alfa Wassermann/Norgine/Bama-Geve's Xifaxan for IBS-D, the potential introduction of four pipeline drugs for the treatment of IBS, and the increasing prevalent cases of IBS.
* The main corporate strategy trend in the IBS market is for companies to enter into partnerships for the successful co-development and co-marketing of products in the different global regions.
* The most pressing unmet need in the IBS market is for the development of drugs with improved efficacy.

Scope

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156 (1.413.485.7001 Int'l)

You may also be interested in these related reports:

- PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2023
- PharmaPoint: Irritable Bowel Syndrome - 5EU Drug Forecast and Market Analysis to 2023
- PharmaPoint: Irritable Bowel Syndrome - US Drug Forecast and Market Analysis to 2023
- PharmaPoint: Irritable Bowel Syndrome - Japan Drug Forecast and Market Analysis to 2023
- PharmaPoint: Macular Edema and Macular Degeneration - Global Drug Forecast and Market Analysis to 2023